Thiopurine S-methyltransferase phenotype-genotype correlation in hemodialyzed patients

Pharmacological Reports

Volumn 58, Issue 6, 2006, Pages 973-978

  Chrzanowska, Maria ^a   Kurzawski, Mateusz ^b   Droździk, Marek ^b   Mazik, Marta ^a   Oko, Andrzej ^a   Czekalski, Stanisław ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Dialysis; Genotype; Phenotype; Renal transplantation; TPMT

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME ASSAY; ERYTHROCYTE; FEMALE; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEMODIALYSIS PATIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK REDUCTION; WILD TYPE;

EID: 33846306376     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES et al.: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med, 1998, 129, 716-718.
2. Chocair P, Duley J, Simmonds H, Cameron J: The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation, 1992, 53, 1051-1056.
3. Coulthard SA, Rabello C, Robson J, Howell C, Minto L, Middleton PG, Gandhi MK et al.: A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br J Haematol, 2000, 110, 599-604.
4. de la Moureyre C, Debuysere H, Mastain B, Vinner E, Marez D, Lo Guidice JM, Chevalier D et al.: Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in European population. Br J Pharmacol, 1998, 125, 879-887.
5. Evans W: Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit, 2004, 26, 186-191.
6. Evans W: Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way. Pharmacogenetics, 2002, 12, 421-423.
7. Ford L, Prout C, Gaffney D, Berg J: Whose TPMT activity is it anyway? Ann Clin Biochem, 2004, 41, 498-500.
8. Formea CM, Myers-Huentelman H, Wu R, Crabtree J, Fujita S, Hemming A, Reed A et al.: Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am J Transplant, 2004, 4, 1810-1817.
9. Ganiere-Monteil C, Medard Y, Lejus C, Bruneau B, Pineau A, Fenneteau O, Bourin M et al.: Phenotype and genotype for thiopurine methyltransferase activity in French Caucasian population: impact of age. Eur J Clin Pharmacol, 2004, 60, 89-96.
10. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, Kennedy MA: Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 2003, 18, 395-400.
11. Kröplin T, Iven H: Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S-methyltransferase. Eur J Clin Pharmacol, 2000, 56, 343-345.
12. Kröplin T, Weyer N, Gutsche S, Iven H: Thiopurine S-methyltransferase activity in human erythrocytes: new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol, 1998, 54, 265-271.
13. Kurzawski M, Dziewanowski K, Gawronska-Szklarz B, Domanski L, Drozdzik M: The impact of thiopurine S-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients. Ther Drug Monit, 2005, 27, 435-441.
14. Kurzawski M, Gawrońska-Szklarz B, Droździk M: Frequency distribution of thiopurine S-methyltransferase alleles in a Polish population. Ther Drug Monit, 2004, 26, 541-545.
15. Lennard L: Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions. Ther Drug Monit, 1998, 20, 527-531.
16. Lysaa R, Giverhaug T, Wold H, Aarbakke J: Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol, 1996, 49, 393-396.
17. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M: Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford), 1999, 38, 640-644.
18. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pin CH et al.: Mercaptopurine therapy intolerance related to heterozygosity at the thiopurine methyltransferase gene locus. J Natl Cancer Inst, 1999, 91, 2001-2008.
19. Sanderson J, Ansari A, Marinaki T, Duley J: Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem, 2004, 41, 294-302.
20. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, Zanger UM et al.: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics, 2004, 14, 407-417.
21. Tassaneeyakul W, Srimarthpirom S, Reungjui S, Romphruk A: Azathioprine-induced fatal myrelosuppression in a renal-transplant recipient who carried heterozygous TPMT*1/*3C. Transplantation, 2003, 76, 265-266.
22. Thervet E, Anglicheau D, Toledano N, Houllier AM, Noel LH, Kreis H, Beaune P et al.: Long-term results of TMPT activity monitoring in azathioprine-treated renal allograft recipients. J Am Soc Nephrol, 2001, 12, 170-176.
23. Weinshilboum R, Sladek S: Mercaptopurine pharmaco-genetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet, 1980, 32, 651-662.
24. Weyer N, Kröplin T, Fricke L, Iven H: Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Pharmacol, 2001, 57, 129-136.
25. Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM: Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs. Eur J Clin Pharmacol, 2004, 60, 5-10.
26. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med, 1997, 126, 608-614.